Entera Bio News

News

Ticker

ENTX

ISIN

IL0011429839

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Entera Bio Eulerpool News

Entera Bio Stock News

Entera Bio is being monitored by journalists and investors worldwide. We gather the latest Entera Bio news here.

Entera Bio Stock Press Releases

Entera Bio regularly publishes news on the company's website that are relevant for investors.

November 10•
Entera Bio
Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
October 6•
Entera Bio
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
September 21•
Entera Bio
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET
September 12•
Entera Bio
Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 12•
Entera Bio
Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
August 11•
Entera Bio
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022
July 26•
Entera Bio
Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting
July 18•
Entera Bio
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position
June 17•
Entera Bio
Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities
May 12•
Entera Bio
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
May 5•
Entera Bio
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
April 28•
Entera Bio
Entera Bio to Report First Quarter 2022 Financial Results on May 12
March 22•
Entera Bio
Entera Bio to Present at 2022 Maxim Virtual Growth Conference
February 17•
Entera Bio
Entera Bio to Present at Aegis Virtual Conference on February 23rd
January 4•
Entera Bio
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
November 10•
Entera Bio
Entera Bio Reports Third Quarter 2021 Financial Results
October 28•
Entera Bio
Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs
October 6•
Entera Bio
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session
September 1•
Entera Bio
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
August 23•
Entera Bio
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021
August 23•
Entera Bio
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference
August 16•
Entera Bio
Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates
August 13•
Entera Bio
Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021
August 2•
Entera Bio
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
June 28•
Entera Bio
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
June 23•
Entera Bio
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
June 17•
Entera Bio
Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union
May 20•
Entera Bio
Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates
April 20•
Entera Bio
Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors
April 15•
Entera Bio
Entera Appoints Ramesh Ratan as Chief Financial Officer

Entera Bio News 2026

This page contains all current news, analysis and press releases for Entera Bio stock (ENTX, ISIN: IL0011429839). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Entera Bio.

Entera Bio Stock

Entera Bio Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide.